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ORIGINAL INVESTIGATION
Metabolically-inactive glucagon-like 
peptide-1(9–36)amide confers selective 
protective actions against post-myocardial 
infarction remodelling
Emma Robinson1, Mitchel Tate1, Samuel Lockhart1, Claire McPeake1, Karla M. O’Neill1, Kevin S. Edgar1, 
Danielle Calderwood2, Brian D. Green2, Barbara J. McDermott1 and David J. Grieve1*
ABSTRACT 
Background: Glucagon-like peptide-1 (GLP-1) therapies are routinely used for glycaemic control in diabetes and 
their emerging cardiovascular actions have been a major recent research focus. In addition to GLP-1 receptor activa-
tion, the metabolically-inactive breakdown product, GLP-1(9–36)amide, also appears to exert notable cardiovascular 
effects, including protection against acute cardiac ischaemia. Here, we specifically studied the influence of GLP-1(9–
36)amide on chronic post-myocardial infarction (MI) remodelling, which is a major driver of heart failure progression.
Methods: Adult female C57BL/6 J mice were subjected to permanent coronary artery ligation or sham surgery prior 
to continuous infusion with GLP-1(9–36)amide or vehicle control for 4 weeks.
Results: Infarct size was similar between groups with no effect of GLP-1(9–36)amide on MI-induced cardiac hypertro-
phy, although modest reduction of in vitro phenylephrine-induced H9c2 cardiomyoblast hypertrophy was observed. 
Whilst echocardiographic systolic dysfunction post-MI remained unchanged, diastolic dysfunction (decreased mitral 
valve E/A ratio, increased E wave deceleration rate) was improved by GLP-1(9–36)amide treatment. This was associ-
ated with modulation of genes related to extracellular matrix turnover (MMP-2, MMP-9, TIMP-2), although interstitial 
fibrosis and pro-fibrotic gene expression were unaltered by GLP-1(9–36)amide. Cardiac macrophage infiltration was 
also reduced by GLP-1(9–36)amide together with pro-inflammatory cytokine expression (IL-1β, IL-6, MCP-1), whilst 
in vitro studies using RAW264.7 macrophages revealed global potentiation of basal pro-inflammatory and tissue pro-
tective cytokines (e.g. IL-1β, TNF-α, IL-10, Fizz1) in the presence of GLP-1(9–36)amide versus exendin-4.
Conclusions: These data suggest that GLP-1(9–36)amide confers selective protection against post-MI remodelling 
via preferential preservation of diastolic function, most likely due to modulation of infiltrating macrophages, indicat-
ing that this often overlooked GLP-1 breakdown product may exert significant actions in this setting which should be 
considered in the context of GLP-1 therapy in patients with cardiovascular disease.
Keywords: Glucagon-like peptide-1 (GLP-1), GLP-1(9–36)amide, Myocardial infarction, Cardiac remodelling
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Background
It is well established that glucagon-like peptide-1 (GLP-
1), which is now routinely exploited in the clinical 
management of hyperglycaemia associated with type 2 
diabetes (e.g. exenatide, saxagliptin), exerts important 
cardiovascular actions in both health and disease [1]. For 
example, GLP-1 mediates key physiological effects on 
blood pressure, vascular tone, and cardiac structure and 
function [2–6], whilst it is widely reported to be protec-
tive against both experimental and clinical cardiovascu-
lar disease in normoglycaemia and diabetes [7–13]. With 
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regard to potential cardiovascular applications of GLP-1 
therapy, one of the most studied areas has been in the set-
ting of ischaemic heart disease, to which diabetic patients 
are particularly predisposed [14]. It has been known for 
several years that both GLP-1 receptor (GLP-1R) agonists 
and dipeptidyl peptidase-4 (DPP-4) inhibitors, which 
increase endogenous GLP-1, protect cardiomyocytes 
from acute ischaemic damage and promote functional 
recovery after experimental myocardial infarction (MI) 
[15]. More recently, GLP-1 analogues have been reported 
to improve post-MI survival and cardiac structure/func-
tion in rodent models independently of infarct size and 
metabolic effects [16, 17], suggesting direct protection 
against ischaemic heart failure. Indeed, our group have 
built on these findings to show that the GLP-1 mimetic, 
exendin-4, exerts specific benefits on post-MI remodel-
ling in normoglycaemia via selective actions on inflam-
mation and the extracellular matrix (ECM), which are 
characteristic features of the diabetic heart [18, 19], high-
lighting cell-targeted GLP-1-based therapies as a poten-
tial novel approach in this setting.
Interestingly, whilst the cardiovascular effects of 
native GLP-1(7–36)amide and its stable analogues are 
well established, its breakdown product, GLP-1(9–36)
amide [hereafter referred to as GLP-1(9–36)], which is 
produced further to degradation by DPP-4 and is meta-
bolically inactive [20], also appears to mediate important 
signalling actions in the cardiovascular system. For exam-
ple, GLP-1(9–36) is reported to promote dose-dependent 
vascular relaxation ex vivo and to inhibit hyperglycaemia-
induced mitochondrial reactive oxygen species (ROS) 
generation both in vitro and in vivo [4, 5, 21, 22]. With 
regard to cardiac ischaemia, protective actions of GLP-
1(7–36)amide and exendin-4 against reperfusion injury 
were found to be resistant to the GLP-1R antagonist, 
exendin(9–39), and to persist in GLP-1R knockout mice, 
with the former being inhibited by the DPP-4 inhibitor, 
sitagliptin, indicating that they were likely to be medi-
ated by GLP-1(9–36) and/or GLP-1R-independent path-
ways [5, 23]. Indeed, acute treatment of ex  vivo mouse 
hearts with GLP-1(9–36) prior to ischaemia–reperfusion 
resulted in improved functional recovery and reduced 
infarct size, and conferred additional cardioprotective 
actions to those mediated by exendin-4 [24], suggesting 
that the metabolically-inactive GLP-1 peptide may acti-
vate distinct cardiovascular signalling pathways. Nota-
bly, the evident importance of GLP-1(9–36)-mediated 
actions (together with the known pleiotropic actions of 
GLP-1 signalling) may at least partly explain the appar-
ently disappointing results of recent large-scale DPP-4 
inhibitor trials which failed to demonstrate any signifi-
cant benefits on cardiovascular outcomes in diabetic 
patients [1, 25, 26]. It is therefore clearly important to 
assess the potential of cardioactive metabolite pathways 
to the reported protective actions of GLP-1. Further to 
our recent observation that GLP-1 mediates distinct ben-
eficial effects on post-infarction remodelling, the aim of 
this study was to specifically investigate whether meta-
bolically-inactive GLP-1(9–36) also plays a key role in 
this setting, by employing a normoglycaemic experimen-
tal model to directly assess its cardioprotective contribu-
tion. Here, we report selective GLP-1(9–36)-mediated 
protection against diastolic dysfunction and myocardial 
inflammation post-MI together with specific modulation 
of macrophage response genes, actions which are clearly 
important to consider when assessing the likely effective-
ness of GLP-1 targeting strategies in this setting.
Methods
Experimental model
Female C57BL/6  J mice (8–12  weeks; Harlan UK) were 
used throughout this study and were housed under con-
stant climatic conditions with free access to food and 
water. All experimental procedures were performed in 
accordance with the Guidance on the Operation of the 
Animals (Scientific Procedures) Act, 1986 (UK) and 
approved by the Queen’s University Belfast Animal Wel-
fare and Ethical Review Body. Mice were randomised 
prior to permanent ligation of the left anterior descend-
ing coronary artery under 2 % isofluorane/oxygen anaes-
thesia (with pre/post-operative buprenorphine analgesia, 
0.05  mg/kg i.m., as required) or sham surgery, which 
involved an identical procedure with the exception of 
coronary artery ligation. Females were used as they dis-
play significantly lower peri-operative mortality versus 
males, and also to allow a direct comparison with our 
previous work relating to the cardioprotective actions 
of exendin-4 post-MI [18, 27]. Similarly, MI or sham-
operated mice were randomly assigned for chronic infu-
sion with either GLP-1(9–36) or saline control, using the 
same concentration (25 nmol/kg/day; GL Biochem, aver-
age purity 90  %) as used in our previous GLP-1 studies 
[18, 28], via an osmotic minipump (Alzet model 1004) 
implanted immediately after MI/sham surgery. After 
4  weeks, animals were either terminally anaesthetised 
(2 % isofluorane/oxygen) and hearts arrested in diastole 
by injection of 10 % KCl, excised and fixed in 10 % neu-
tral-buffered formalin solution, or sacrificed by sodium 
pentobarbitone overdose (200  mg/kg i.p.) prior to exci-
sion of hearts which were frozen in liquid nitrogen and 
stored at −80 °C for further analyses.
Assessment of plasma glucose
Terminal blood samples were collected by cardiac 
puncture into heparinised tubes and centrifuged at 
10,000g for 10  min to obtain plasma fractions which 
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were analysed for glucose using an enzymatic assay kit 
(GMRD-002A using glucose oxidase, Analox Ltd) and 
detected on a GM7 Micro-Stat Analyser (Analox Instru-
ments Ltd).
Infarct size
Excised hearts were perfused retrogradely with Evans 
blue dye (1  % in saline) in order to determine area at 
risk prior to slicing into five serial transverse sections 
(1  mm) which were incubated in 1  % triphenyltetra-
zolium chloride at 37  °C to identify infarcted myocar-
dium. Infarct area, area at risk and total left ventricular 
(LV) area from each section were measured using com-
puterised planimetry (ImageJ), and totalled for all sec-
tions. Infarct size was expressed as a percentage of area 
at risk.
Echocardiography
Mice were anaesthetised with 1.5  % isofluorane/oxy-
gen, placed on a warming pad, and imaged in the supine 
position using a Vevo770 ultrasound system with high-
frequency 45  MHz RMV707B scanhead (VisualSonics). 
M-mode parasternal short-axis scans at papillary muscle 
level were used to quantify interventricular septal thick-
ness in diastole (IVSD), and left ventricular end-diastolic 
(LVEDD) and end-systolic diameters (LVESD), from 
which  % fractional shortening was calculated using the 
equation (LVEDD−LVESD)/LVEDD*100. Parasternal 
long-axis scans were used to provide additional data on 
LV end-diastolic (LVEDV) and end-systolic volumes 
(LVESV) and ejection fraction, whilst pulse-wave Dop-
pler was used to assess mitral valve flow (E/A ratio) and 
E wave deceleration rate, as reliable measures of diastolic 
function. All images were analysed by the same observer 
in a blinded manner in order to minimise variability and 
bias.
Cardiac morphometry and in vitro cardiomyocyte studies
Following sacrifice, whole and sectioned hearts were 
weighed and indexed to total body weight, as a surrogate 
measure of cardiac hypertrophy. To investigate direct 
effects of GLP-1(9–36) on in vitro cardiomyocyte hyper-
trophy, complementary studies were conducted in rat 
ventricular H9c2 cardiomyoblasts maintained in DMEM 
containing 10  % FCS, 100  U/ml penicillin and 100  µg/
ml streptomycin. At passage, they were plated, cultured 
to ~50  % confluency and serum-starved for 24  h prior 
to incubation with phenylephrine (1 μmol/L for 96 h) to 
induce hypertrophy in the presence or absence of GLP-
1(9–36) (0.1  μmol/L) [18]. Cell cross-sectional area was 
quantified by blinded digital image analysis (NIS-Ele-
ments) as an index of hypertrophy.
Histology and immunohistochemistry
All histological analyses were performed on fixed par-
affin-embedded LV sections (5  μm). Cardiac intersti-
tial fibrosis was assessed by picrosirius red staining 
(0.1 % w/v), excluding coronary vessels and perivascular 
regions. Data were quantified by digital image analysis 
(NIS-Elements, Nikon) with the observer blinded to sam-
ple identity. Immunocytochemistry for CD45 and F4/80 
was performed using rat polyclonal (553076, 1:200; BD 
Bioscience) and rat monoclonal (MCA497GA, 1:200; 
AbD Serotec) antibodies, respectively, followed by sec-
ondary rabbit anti-rat IgG (P0450, 1:100; Dako) staining, 
using diaminobenzidine as the chromogen and nuclear 
counterstaining with haematoxylin.
Real‑time RT‑PCR
Total RNA was extracted from LV homogenate or cells 
using TRI reagent (Sigma-Aldrich), and cDNA synthe-
sised by reverse transcription (Applied Biosystems). 
mRNA expression was then analysed by reverse tran-
scription polymerase chain reaction (RT-PCR) using 
fluorescent SYBR Green (Prism 7300, Applied Biosys-
tems) with the following primers (5′–3′): procollagen IαI, 
forward CCTCAGGGTATTGCTGGACAAC, reverse 
TTGATCCAGAAGGACCTTGTTTG; fibronectin, for-
ward CCGGTGGCTGTCAGTCAGA, reverse CCGTT 
CCCACTGCTGATTTATC; CTGF, forward GCTGCCT 
ACCGACTGGAAGAC, reverse GAACAGGCGCT 
CCACTCTG; MMP-2, forward GACAAGTTCTGGAGA 
TACAATGAAGTG, reverse, CAGGTTATCAGGGAT 
GGCATTC; MMP-9, forward GTGATCCCCACTTAC 
TATGGAAACTC, reverse, GTGCTACACCAAGGC 
GTGC; TIMP-2, forward GATTCAGTATGAGATC 
AAGCAGATAAAGA, reverse, GCGAGACCCCGCACA 
CT; IL-1β, forward TGTGGCTGTGGAGAAGCTGT, 
reverse CAGCTCATATGGGTCCGAGA; IL-6, forward 
CACGGCCTTCCCTACTTCAC, reverse TGCAAGT 
GCATCATCGTTGT; MCP-1, forward ATGCTTCTGG 
GCCTGCTG, reverse GGTGATCCTCTTGTAGCTC 
TCC; TNF-α, forward, ACTCAACAAACTGCCCTTC 
TGAG, reverse TTACAGCTGGTTTCGATCCATTT; 
Arg1, forward TTATCGAGCGCCTTTCTCAA, reverse 
TGGTCTCTCACGTCATACTCTGT; Fizz1, forward 
TCCCAGTGAATACTGATGAGA, reverse CCACTCTG 
GATCTCCCAAGA; IL-10, forward TGCAGGACTT 
TAAGGGTTACTTGG, reverse GGCCTTGTAGAC 
ACCTTGGTC; TGF-β3, forward GGAGAGAGTCCAAC 
TGGGTCTG, reverse ACATTTTCCAGTATGTCTCC 
ATTGG. β-actin (primer sequence 5′–3′: forward CGTG 
AAAAGATGACCCAGATCA, reverse TGGTACGACC 
AGAGGCATACAG) or GAPDH (primer sequence 
5′–3′: forward ACTTTGTCAAGCTCATTTCC, reverse 
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GCAGCGAACTTTATTGATG) was used for normalisa-
tion by the comparative Ct method [29].
RAW264.7 macrophage culture
RAW264.7 murine macrophages (ATCC® TIB-71™) were 
maintained in DMEM containing 10  % FCS, 100  U/ml 
penicillin and 100 µg/ml streptomycin. At passage, cells 
were split into six-well plates, each containing ~1 million 
cells, prior to incubation in the presence or absence of 
exendin-4 or GLP-1(9–36) (10 nmol/L) for 4 h. RNA and 
cDNA were then prepared for real-time RT-PCR mRNA 
expression analysis of IL-1β, TNF-α, Arg1, Fizz1, IL-10, 
IL-12, IL-6 and TGF-β3 using fluorescent SYBR Green 
and GAPDH for normalisation.
Statistical analysis
Data are expressed as mean ± SEM and were analysed by 
either an unpaired t test or one-way ANOVA followed by 
a Bonferroni’s multiple comparison test, using GraphPad 
Prism software. P < 0.05 was considered to be statistically 
significant.
Results
Metabolic data
Body weight was not different between groups (sham 
control: 21.4 ±  0.4, MI control: 21.5 ±  0.2, sham GLP-
1(9–36): 21.6 ± 0.5, MI GLP-1(9–36): 21.0 ± 0.3 g; n = 8, 
P  =  NS). Similarly, chronic infusion with GLP-1(9–36) 
had no effect on plasma glucose (MI control: 8.7 ±  0.2, 
MI GLP-1(9–36): 9.2 ± 0.2 mmol/L; n = 8–9, P = NS).
Infarct size
Importantly, both area at risk (control: 75.3 ± 3.4, GLP-
1(9–36): 79.6  ±  0.4  %LV; n  ≥  5) and infarct size (con-
trol: 47.1 ± 4.6, exendin-4: 47.2 ± 1.2 %LV; n ≥ 5) were 
comparable between MI groups at 4  weeks (Fig.  1a–b), 
thereby facilitating specific investigation of direct effects 
on chronic remodelling. Similarly, survival at 4  weeks 
post-MI was not different between groups (MI control: 
90.0 %, n = 30; MI GLP-1(9–36): 87.0 %, n = 23; P = NS). 
No deaths were observed in the sham groups (n = 36).
Cardiomyocyte hypertrophy
Chronic infusion with GLP-1(9–36) had no effect on MI-
induced myocardial hypertrophy, as assessed by echocardi-
ographic IVSD (Fig. 1c) and cardiac morphometry (whole 
heart and LV/body weight ratio, Fig.  1d–e), although 
in  vitro phenylephrine-induced hypertrophy of H9c2 car-
diomyoblasts was reduced by GLP-1(9–36) (Fig. 1f).
Cardiac function
Echocardiography data are presented in Fig.  2. Impor-
tantly, heart rate remained similar between all groups 
(sham control: 454  ±  15, MI control: 493  ±  15, 
sham GLP-1(9–36): 453  ±  0.10, MI GLP-1(9–36): 
485 ± 12 bpm; n = 8–19, P = NS). LV diastolic and sys-
tolic chamber size, as measured by LVEDV and LVESV, 
respectively, which were both increased after MI, were 
unaltered by GLP-1(9–36), whilst LV systolic dysfunction 
post-MI, indicated by reduced ejection fraction and frac-
tional shortening, was also unaffected (Fig. 2a–d). How-
ever, decreased mitral valve E/A ratio and increased E 
wave deceleration rate post-MI, which are reliable indica-
tors of diastolic dysfunction (reflecting reduced LV filling 
and compliance, respectively) were both attenuated by 
GLP-1(9–36) treatment (Fig. 2e–f).
Extracellular matrix remodelling
Interstitial fibrosis, assessed by picrosirius red staining, 
was markedly increased 4 weeks post-MI but was unal-
tered by GLP-1(9–36) (Fig.  3). Similarly, chronic treat-
ment with GLP-1(9–36) had no effect on MI-induced 
mRNA expression of key pro-fibrotic genes, procol-
lagen IαI, fibronectin and CTGF (Fig.  4a–c). However, 
GLP-1(9–36) treatment induced MMP-9 mRNA expres-
sion and attenuated increased TIMP-2 mRNA expres-
sion post-MI, and also tended to reduce MMP-2 mRNA 
(Fig. 4d–f).
Myocardial inflammation
Cardiac infiltration of both CD45+ and F4/80+ cells was 
increased by approximately 5-fold and threefold, respec-
tively, in MI versus sham animals (Fig.  5a–b). Whilst 
numbers of CD45+ leukocytes were comparable between 
control and GLP-1(9–36)-treated MI hearts, MI-induced 
infiltration of F4/80+ macrophages were markedly 
reduced by GLP-1(9–36). Similarly, increased mRNA 
expression of pro-inflammatory IL-1β, IL-6 and MCP-1 
in MI hearts was reduced by GLP-1(9–36), although 
mRNA expression of the key pro-fibrotic cytokine, TGF-
β3, was unaltered between groups (Fig. 5c–f).
Cell studies
In order to investigate direct inflammatory effects of 
GLP-1(9–36), complementary studies were conducted in 
RAW264.7 macrophages (Fig.  6). Notably, treatment of 
these cells for 24 h with 10 nmol/L GLP-1(9–36) resulted 
in a general increase in mRNA expression of several mac-
rophage response genes, associated with both an M1 
(IL-1β, TNF-α, Arg1, IL-12, IL-6) and M2 (Fizz1, IL-10, 
TGF-β3) cell phenotype, compared with cells incubated 
with the same concentration of exendin-4.
Discussion
In this study, we clearly demonstrate that metaboli-
cally-inactive GLP-1(9–36) exerts selective actions on 
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experimental post-MI remodelling, a finding which 
has obvious clinical significance. Specifically, we have 
shown that GLP-1(9–36) is protective against the devel-
opment of post-MI diastolic dysfunction and modulates 
myocardial inflammation, but appears to have limited 
effects on ECM and cardiomyocyte remodelling in this 
setting. Complementary cell studies found that acute 
GLP-1(9–36) treatment potentiated basal macrophage 
Fig. 1 Effect of GLP-1(9–36) on infarct size and cardiomyocyte remodelling post-MI. a area at risk and b infarct size assessed 4 weeks following MI 
(n = 5–6). c Interventricular septal thickness in diastole (IVSD), assessed by echocardiography (n = 11–19). d–e cardiac morphometry normalised to 
body weight (n = 11–17). f phenylephrine-induced hypertrophy in H9c2 cardiomyoblasts (n = 4). White columns, sham (c–e) or untreated cells (f); 
black columns, MI (a–e) or phenylephrine-treated cells (f); mean ± SEM. **P < 0.01, ***P < 0.001 versus corresponding sham/untreated control
Fig. 2 Effect of GLP-1(9–36) on cardiac function post-MI. a LV end-diastolic volume (LVEDV), b LV end-systolic volume (LVESV), c LV ejection fraction, 
d LV fractional shortening, e mitral valve E/A ratio, and f E wave deceleration rate, assessed by echocardiography (n = 8–19). White columns, sham; 
black columns, MI mean ± SEM. ***P < 0.001 versus corresponding sham. †††P < 0.001 versus corresponding MI
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Fig. 3 Effect of GLP-1(9–36) on interstitial fibrosis post-MI. a–d Representative LV sections stained with picrosirius red to assess interstitial fibrosis, 
with e quantification data (n = 5–6). White columns, sham; black columns, MI mean ± SEM. ***P < 0.001 versus corresponding sham
Fig. 4 Effect of GLP-1(9–36) on extracellular matrix gene expression post-MI. LV mRNA expression of a procollagen IαI, b fibronectin, c CTGF, d 
MMP-2, e MMP-9, and f TIMP2 by real-time RT-PCR (n = 5-6). White columns, sham, black columns, MI mean ± SEM. *P < 0.05, **P < 0.01 versus cor-
responding sham; †P < 0.05 versus corresponding MI
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response gene expression to a greater extent than 
exendin-4, indicating that this often overlooked GLP-1 
breakdown product may exert important differential 
actions on infiltrating inflammatory cells, which may 
thereby influence post-MI remodelling.
Choice of experimental model for specific study 
of GLP‑1(9–36) in chronic post‑MI remodelling
The rationale for this study was based on the fact 
that GLP-1(9–36) has been reported to mediate sev-
eral important cardiovascular actions in experimental 
Fig. 5 Effect of GLP-1(9–36) on myocardial inflammation post-MI. Representative LV sections stained for a CD45 and b F4/80, together with mean 
quantification data by analysis of 10 high power fields per section (n = 5–6). LV mRNA expression of cytokines c IL-1β, d IL-6, e MCP-1, and f TGF-β3 
by real-time RT-PCR (n = 5–6). White columns, sham, black columns, MI mean ± SEM. **P < 0.01, ***P < 0.001 versus corresponding sham; †P < 0.05, 
†††P < 0.001 versus corresponding MI
Fig. 6 Effect of GLP-1(9–36) on inflammatory gene expression in RAW264.7 macrophages. mRNA expression of a IL-1β, b TNF-α, c Arg1, d Fizz1, e 
IL-10, f IL-12, g IL-6, and h TGF-β3 by real-time RT-PCR (n = 5–12). Mean ± SEM. *P < 0.05, **P < 0.01 versus corresponding control
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models, including promotion of vascular relaxation, 
modulation of cardiac function, and protection against 
ischemia–reperfusion injury [4, 5, 24]. As we have 
recently shown that the stable GLP-1 mimetic, exendin-4, 
exerts selective protection against chronic post-MI 
remodelling, and both GLP-1R activation and GLP-1(9–
36) reduce infarct size in response to acute ischaemia 
[18, 24], it seemed logical to investigate whether GLP-
1(9–36) may also mediate specific actions on the remote 
myocardium after chronic ischaemia. This may be par-
ticularly relevant to the clinical setting given the increas-
ing interest in the cardiovascular actions of established 
GLP-1 therapies in diabetic patients with heart failure 
[1, 25, 26], particularly DPP-4 inhibitors, which inhibit 
the breakdown of native GLP-1(7–36)amide, thereby 
significantly reducing circulating levels of its breakdown 
product, GLP-1(9–36). In this regard, it is important to 
note that our chosen experimental approach employing 
continuous infusion of GLP-1(9–36) commencing imme-
diately after MI or sham surgery, as used in our previ-
ous study [18], facilitated specific investigation of direct 
effects on chronic post-MI remodelling in the absence 
of indirect effects further to reported benefits on acute 
infarct remodelling in response to GLP-1 treatment [10, 
11, 30]. Indeed, area at risk and infarct size assessed at 
4 weeks post-MI were similar between control and GLP-
(9–36)-treated mice indicating that the observed chronic 
ventricular remodelling changes were likely to be due 
to direct cardiac actions of the peptide. Furthermore, as 
expected, metabolically inactive GLP-1(9–36) had no 
effect on either body weight or plasma glucose.
GLP‑1(9–36) has minimal actions on cardiomyocyte 
remodelling
In contrast to exendin-4, which we recently reported to 
exert modest protection against post-MI cardiomyocyte 
remodelling [18], GLP-1(9–36) treatment in MI mice had 
no effect on cardiac morphology, as assessed by echocar-
diographic IVSD and post-mortem heart and LV mass, 
although a small reduction in in  vitro phenylephrine-
induced H9c2 cardiomyoblast hypertrophy was observed. 
Indeed, although several studies have shown that GLP-1 
is protective against acute cardiomyocyte remodelling 
[5, 23, 31], it appears that GLP-1 may have limited direct 
effects on this cell type in vivo [1, 18]. However, that is not 
to say that indirect modulation of cardiomyocyte auto-
crine or paracrine signalling by GLP-1 peptides should be 
discounted. As far as we are aware, the effects of GLP-
1(9–36) on in vivo cardiomyocyte remodelling have not 
been previously investigated, although several groups 
have reported beneficial actions of GLP-1(9–36) on car-
diac contractile function. For example, GLP-1(9–36) 
was shown to reduce infarct size and improve functional 
recovery after ischaemia–reperfusion in isolated mouse 
hearts, whilst the beneficial effects of GLP-1R activation 
in this setting persisted in the absence of a functional 
GLP-1R or in the presence of the GLP-1R antagonist, 
exendin(9–39), and were abolished by the DPP-4 inhibi-
tor, sitagliptin [5, 23], strongly suggesting that these 
effects are mediated by GLP-1(9–36). Indeed, selective 
disruption of the cardiomyocyte GLP-1R demonstrated 
that it was not required for GLP-1 agonist-induced car-
dioprotection [32], further highlighting a potential role 
for GLP-1(9–36). Similarly, continuous infusion of both 
native GLP-1(7–36)amide and GLP-1(9–36) improved 
systolic/diastolic function and myocardial metabolism in 
dogs with rapid pacing-induced dilated cardiomyopathy, 
although GLP-1(9–36) failed to increase cardiac output 
during regional myocardial ischaemia in pigs [12, 33].
GLP‑1(9–36) specifically protects against diastolic 
dysfunction post‑MI
Here, we found that whilst GLP-1(9–36) had no effect on 
echocardiographic systolic function post-MI, as indexed 
by LVESV, ejection fraction and fractional shortening, 
GLP-1(9–36) significantly attenuated diastolic dysfunc-
tion, as indicated by increased mitral valve E/A ratio 
(improved LV filling) and reduced E wave deceleration 
rate (improved LV compliance), although LV dilatation 
associated with MI remained unchanged. It therefore 
appears that GLP-1(9–36) promotes preservation of car-
diac function post-MI, although it should be noted that 
the extent of this effect may be less pronounced than 
that observed with exendin-4 in the same model [18]. 
Diastolic function is known to be particularly sensitive 
to ECM alterations so given the improvement in mitral 
valve flow in GLP-1(9–36)-treated mice, it would seem 
logical to expect parallel reduction of cardiac fibrosis. 
However, interstitial fibrosis in MI mice was not affected 
by GLP-1(9–36). Similarly, pro-fibrotic gene expres-
sion was largely unaltered in hearts from GLP-1(9–36)-
treated animals, although mRNA expression of TIMP2 
was reduced in MI GLP-1(9–36) mice in parallel with 
a tendency towards reduced expression of its main tar-
get, MMP-2, a major driving force for ECM remodelling 
which is upregulated in MI [34]. Indeed, MMP-9, which 
is typically thought to promote adverse ECM remodel-
ling [35], was oppositely regulated after MI in the GLP-
1(9–36) treated animals compared to control, thereby 
highlighting differential actions on the ECM which may 
underlie the observed attenuation of diastolic dysfunc-
tion. Taken together, these data would appear to sug-
gest that GLP-1(9–36) may influence ECM turnover 
rather than cardiac fibrosis per se, thereby resulting in 
improved LV relaxation, compliance, and diastolic func-
tion, although a more robust analysis of ECM signalling 
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is clearly required before any definite conclusions can be 
drawn.
GLP‑1(9–36) reduces myocardial inflammation via specific 
effects on infiltrating macrophages
It is becoming increasingly evident that myocardial 
inflammation represents a key regulator of post-MI 
remodelling, which directs specific actions on individ-
ual components in this setting, but which is thought to 
preferentially target the ECM [36]. Indeed, we have pre-
viously reported that the GLP-1 mimetic, exendin-4, 
protects against adverse cardiac remodelling in both 
normoglycaemic and diabetic mice via specific actions 
on infiltrating inflammatory cells [18, 37]. In this regard, 
whilst GLP-1(9–36) did not affect the marked myocar-
dial infiltration of CD45+ leukocytes associated with 
MI, increased numbers of F4/80+ macrophages, which 
are particularly prevalent in the ischaemic heart [18, 
38], were normalised by GLP-1(9–36). This was associ-
ated with reduced expression of the pro-inflammatory 
cytokines, IL-1β, IL-6 and MCP-1, which are critical 
for fibroblast differentiation, although mRNA levels of 
TGF-β3 which also upregulates MMP/TIMP expres-
sion, were unaltered [34, 39]. Interestingly, complemen-
tary in  vitro experiments performed using RAW264.7 
murine macrophages revealed a clear potentiation 
of basal mRNA expression of macrophage response 
genes, which are known to regulate tissue remodelling 
and repair, in the presence of GLP-1(9–36) compared 
with exendin-4, which we have previously reported to 
modulate resident and secreted cytokine expression in 
bone marrow-derived cells under both normal and high 
glucose conditions [18, 37, 40, 41]. Importantly, GLP-
1(9–36) appeared to upregulate both pro-inflammatory 
(IL-1β, TNF-α, IL-6, IL-12, Arg1) and tissue protective 
cytokines (IL-10, Fizz1), in addition to TGF-β3 which is 
a major driver of ECM remodelling [38, 39], highlighting 
global activation of macrophage function. It should be 
noted that whilst the employed concentration of GLP-
1(9–36) in these in vitro experiments was based on that 
used in previous studies, it is higher than circulating lev-
els typically found in vivo [24, 42, 43]. Nonetheless, taken 
together with the observation that MI-induced mac-
rophage infiltration was almost completely prevented by 
GLP-1(9–36), these data strongly suggest that this pur-
portedly inactive peptide exerts significant actions which 
are relevant to cardiac remodelling. Whilst these findings 
are consistent with a previous report of GLP-1(9–36)-
mediated inhibition of chemokine-induced migration of 
human CD4-positive lymphocytes [44], which is estab-
lished as an early and critical step in atherogenesis, ours 
is the first study to specifically link an immunomodula-
tory effect of GLP-1(9–36) to cardioprotection. Although 
this apparent modulation of the myocardial inflamma-
tory response by GLP-1(9–36) is most likely to impact 
upon ECM remodelling and thereby explain the observed 
preservation of cardiac function, it is also possible that 
reduced cardiac macrophage infiltration and associ-
ated changes in gene expression may also influence car-
diomyocyte function due to modulation of established 
paracrine communication between these two cell popu-
lations [45]. Interestingly, recent reports that increased 
mitochondrial ROS generation associated with both high 
glucose exposure in human endothelial cells and Alzhei-
mer’s disease in mouse hippocampal tissue, is attenuated 
by GLP-1(9–36) [21, 46, 47], suggest that such antioxi-
dant actions of GLP-1(9–36) may underlie the observed 
attenuation of post-MI remodelling, specific components 
of which are known to be significantly influenced by ROS 
[48].
Conclusion
Although, the precise role of GLP-1(9–36) in the ischae-
mic heart remains unclear and the mechanisms under-
lying its apparent protective actions require detailed 
further investigation, it is evident that such effects are 
likely to be clinically significant so should be considered 
in the context of GLP-1 therapy in patients with cardio-
vascular disease. Indeed, it is possible that the apparently 
disappointing results of the first large-scale cardiovascu-
lar trials of the DPP-4 inhibitors saxagliptin and aloglip-
tin, which are likely to markedly reduce circulating levels 
of GLP-1(9–36), could be at least partly explained by the 
absence of this endogenous GLP-1 breakdown prod-
uct. In support of this supposition, a recent experimen-
tal study reported that administration of a preclinical 
DPP-4 inhibitor, MK-0626, to high fat-fed diabetic mice 
resulted in increased cardiac fibrosis and impaired ven-
tricular function [49]. Together with our previous find-
ings with exendin-4 in the setting of both experimental 
MI and diabetes, the data presented here suggest that 
selective targeting of specific remodelling pathways, 
with consideration of both GLP-1R activation and GLP-1 
breakdown, may overcome the known pleiotropic nature 
of GLP-1 signalling. Such novel approaches utilising, for 
example, specific GLP-1 peptide modification strategies 
[50], may thereby improve the effectiveness of GLP-1-
based strategies for cardiovascular disease.
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